Dennis Schmatz joins Scynexis
Will provide advice to US firm as it advances drug development programme
Scynexis president and chief executive Dr Yves Ribeill, said: ‘His contributions to Scynexis will be important as we aggressively pursue the development of our cyclophilin inhibitor technology platform and the discovery of global health therapeutics for neglected diseases.’
Schmatz was most recently interim president and chief executive of the Medicines for Malaria Venture, a non-profit foundation in Geneva, Switzerland created to discover anti-malarial drugs through public-private partnerships. Previously he was vice president of Merck Research Laboratories USA and head of the Tsukuba Research Institute of Banyu Research Laboratories in Japan.
‘It's an exciting time to be joining the Scynexis team as both their HCV compounds, SCY-635, and their partnered broad-spectrum antifungal compound, MK-3118, advance through clinical development,’ Schmatz said. ‘I see a promising future for Scynexis and am honoured to be a part of it.’
You may also like
Research & Development
COVID-19 immunity lowers the risk of a new pandemic
Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Cytiva enters research partnership with SRTIGET for next-gen genomic medicine
The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens